GEOVAX LABS INC (GOVX)

Company Profile

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is headquartered in Smyrna, Georgia and currently employs 14 full-time employees. The firm is focused on developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using its platforms. Its product pipeline includes ongoing human clinical trials for a COVID-19 and a gene-directed therapy against advanced head and neck cancers. The company is developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02, GEO-EM01, GEO-LM01 and GEO-MM02. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations. Its research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg and Lassa) and Zika virus, as well as immunotherapies for multiple solid tumors. Its wholly owned subsidiary is GeoVax, Inc.

Company Info

GEOVAX LABS INC

1900 Lake Park Drive, Suite 380

Smyrna GEORGIA 30080

P: 16783847220

CEO: David A. Dodd

Employees: 14

Website: https://www.geovax.com/